Literature DB >> 28262469

Diagnosis of Duchenne Muscular Dystrophy in Italy in the last decade: Critical issues and areas for improvements.

Adele D'Amico1, Michela Catteruccia2, Giovanni Baranello3, Luisa Politano4, Alessandra Govoni5, Stefano Carlo Previtali6, Marika Pane7, Maria Grazia D'Angelo8, Claudio Bruno9, Sonia Messina10, Federica Ricci11, Elena Pegoraro12, Antonella Pini13, Angela Berardinelli14, Ksenjia Gorni15, Roberta Battini16, Gianluca Vita10, Federica Trucco9, Marianna Scutifero4, Roberta Petillo4, Paola D'Ambrosio4, Anna Ardissone3, Barbara Pasanisi3, Giuseppe Vita10, Tiziana Mongini11, Maurizio Moggio5, Giacomo Pietro Comi5, Eugenio Mercuri7, Enrico Bertini2.   

Abstract

Despite all the advances in diagnosis and management of Duchenne muscular dystrophy over the past 50 years, the average age at diagnosis in most countries in the world around is still around 4-5 years. This retrospective study investigates the age at diagnosis in Italy in the past 10 years. We report findings from 384 boys who were diagnosed with DMD from 2005 to 2014. The mean age at first medical contact, which raised the suspicion of DMD, was 31 months. The mean age at diagnosis was 41 months. The finding that more frequently brought to suspect a DMD was the incidental finding of consistent elevated creatine kinase serum level detected during routine assessments in children undergoing general anesthesia or with intercurrent illness. This was followed by motor delay and signs of muscle weakness. Initial concerns were raised by general pediatricians (29%), specialists at tertiary centers (35%) or first level hospitals (23%). In children presenting incidental elevated creatine kinase values the diagnosis was achieved earlier than in children presenting a developmental delay. The mean age at diagnosis in our cohort was about 10-12 months lower than that reported in other countries.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  DMD; DMD screening; Delayed diagnosis; Survey

Mesh:

Substances:

Year:  2017        PMID: 28262469     DOI: 10.1016/j.nmd.2017.02.006

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  12 in total

Review 1.  Genetic neuromuscular disorders: living the era of a therapeutic revolution. Part 2: diseases of motor neuron and skeletal muscle.

Authors:  Giuseppe Vita; Gian Luca Vita; Olimpia Musumeci; Carmelo Rodolico; Sonia Messina
Journal:  Neurol Sci       Date:  2019-02-25       Impact factor: 3.307

Review 2.  Clinical management of Duchenne muscular dystrophy: the state of the art.

Authors:  Sonia Messina; Gian Luca Vita
Journal:  Neurol Sci       Date:  2018-09-14       Impact factor: 3.307

3.  Diagnostic delay in patients with FKRP-related muscular dystrophy.

Authors:  Lauren N Coffey; Carrie M Stephan; M B Zimmerman; Chyan K Decker; Katherine D Mathews
Journal:  Neuromuscul Disord       Date:  2021-09-06       Impact factor: 4.296

4.  Clinical and Genetic Characteristics in Young, Glucocorticoid-Naive Boys With Duchenne Muscular Dystrophy.

Authors:  Marianela Schiava; Rachel Amos; Henriette VanRuiten; Michael P McDermott; Williams B Martens; Stephanie Gregory; Anna Mayhew; Elaine McColl; Rabi Tawil; Tracey Willis; Kate Bushby; Robert C Griggs; Michela Guglieri
Journal:  Neurology       Date:  2021-12-02       Impact factor: 9.910

5.  Phenotypic Spectrum of Dystrophinopathy Due to Duchenne Muscular Dystrophy Exon 2 Duplications.

Authors:  Alberto A Zambon; Megan A Waldrop; Roxane Alles; Robert B Weiss; Sara Conroy; Melissa Moore-Clingenpeel; Stefano Previtali; Kevin M Flanigan
Journal:  Neurology       Date:  2021-12-22       Impact factor: 9.910

6.  Genotype characterization and delayed loss of ambulation by glucocorticoids in a large cohort of patients with Duchenne muscular dystrophy.

Authors:  Shu Zhang; Dongdong Qin; Liwen Wu; Man Li; Lifang Song; Cuijie Wei; Chunling Lu; Xiaoli Zhang; Siqi Hong; Mingming Ma; Shiwen Wu
Journal:  Orphanet J Rare Dis       Date:  2021-04-28       Impact factor: 4.123

Review 7.  Facilitations and Hurdles of Genetic Testing in Neuromuscular Disorders.

Authors:  Andrea Barp; Lorena Mosca; Valeria Ada Sansone
Journal:  Diagnostics (Basel)       Date:  2021-04-14

Review 8.  Is it the right time for an infant screening for Duchenne muscular dystrophy?

Authors:  Gian Luca Vita; Giuseppe Vita
Journal:  Neurol Sci       Date:  2020-02-28       Impact factor: 3.307

9.  DMD-related muscular dystrophy in Cameroon: Clinical and genetic profiles.

Authors:  Edmond Wonkam-Tingang; Séraphin Nguefack; Alina I Esterhuizen; David Chelo; Ambroise Wonkam
Journal:  Mol Genet Genomic Med       Date:  2020-06-15       Impact factor: 2.473

10.  Prediagnosis pathway benchmarking audit in patients with Duchenne muscular dystrophy.

Authors:  Vasantha Lakshmi Gowda; Miguel Fernandez; Manish Prasad; Anne-Marie Childs; Imelda Hughes; Sandya Tirupathi; Christian Gaudentius Engelbert Lourens De Goede; Declan O'Rourke; Deepak Parasuraman; Tracey Willis; Samira Saberian; Ian Davidson
Journal:  Arch Dis Child       Date:  2021-07-08       Impact factor: 3.791

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.